Flavoxate (HCl)

Flavoxate (HCl) is antispasmodic agent. It relaxes the muscles of the urinary tract. Flavoxate (HCl) is used to relieve pain, burning, urinary urgency and frequency associated with urinary tract, bladder and prostate infections.

Flavoxate (HCl) is primarily indicated in conditions like Bladder spasm due to catheterization, Dysuria, Fatigue, Nocturia, Pain, Prostatitis, Sedation, Spasticity, Urethritis, Urethrocystitis, Urethrotrigonitis, Urgency and incontinence.

Flavoxate (HCl) is contraindicated in conditions like GI ulceration, Pyloric disease, Obstructive uropathy, GI obstruction.

The following adverse reactions have been observed, but there are not enough data to support an estimate of their frequency. Gastrointestinal: Nausea, vomiting, dry mouth. CNS: Vertigo, headache, mental confusion, especially in the elderly, drowsiness, nervousness. Hematologic: Leukopenia (one case which was reversible upon discontinuation of the drug). Cardiovascular: Tachycardia and palpitation. Allergic: Urticaria and other dermatoses, eosinophilia and hyperpyrexia. Ophthalmic: Increased ocular tension, blurred vision, disturbance in eye accommodation. Renal: Dysuria.

URISPAS ® (flavoxate HCl) should be given cautiously in patients with suspected glaucoma.

URISPAS ® (flavoxate HCl) should be given cautiously in patients with suspected glaucoma.

100 to 200 mg (150 (150)) 8 hourly PO — Scraped Dose — The oral LD 50 for flavoxate HCl in rats is 4273 mg/kg. The oral LD 50 for flavoxate HCl in mice is 1837 mg/kg. It is not known whether flavoxate HCl is dialyzable.

( ) — Not recommended in this age group

No neonatal dosage information is recorded for this medicine yet.

No data regarding the interactions of Flavoxate (HCl) was found.

Tab Store in a well closed container, Below 40°C. Protect from Sunlight and Heat.